ABIONYX Aktie

 

Capital increase of approximately 1.8 million euros Subscription price: 3.10 euros Extension of visibility until the end of 2026 TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces the launch of a capital increase with the removal of preferential subscription rights (“PSR”) for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new shares at a subscription price of 3.10 euros (the “Issuance”). This capital increase is intended to strengthen the Company's cash position. Legal framework of the Issue This transaction is part of a capital increase with cancellation of preferential subscription rights in favor of persons belonging to specific categories, decided today by the Board of Directors, acting ...

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant apoA-1, today announces its financial results for the first half of 2025. Main changes in the consolidated financial statements As mentioned in the publication of the half-yearly revenue figures on August 28, the activity dedicated to the discovery and development of innovative therapies, particularly in sepsis and the rare diseases LCAT deficiency and Norum disease, aimed at improving or even saving patients' lives, has not yet generated any revenue during this half-year. ABIONYX Pharma continues to provide its bioproduct free of charge in the context of compassionate use authorization (CUA) requests for Norum disease. The ABIONYX Pharma group recorded consolidated half-year revenue of €2.1 million in the first half of 2025, which relate...

Consolidated sales of 1 M€ at end March 2025 Cash position of 4.1 M€ at March 31, 2025 before collection of Research Tax Credit of 1.08 M€ Anticipated key milestone: feedback from the EMA by the end of 2025 on the clinical results of LCAT patients treated with a view to marketing authorization TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, today provides an update on its activity and cash position as of March 31, 2025. Selected financial information (IFRS) €m Q1 2024 Q1 2023 Revenue from biotech activity 0.00 0.00 Revenue from IRIS Pharma 0.99 1.40 Total revenue 0.99 1.40 Other revenue 0.00 0.00 Total revenue income and revenue 0.99 1.40 Cash and cash equivalents at the end of the pe 4.09 2.70 ABIONYX Pharma recorded consolidated quarterly sales of nearly €1 millio...

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) April 30, 2025 34,931,012 44,381,742 44,073,317 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. (2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance wit...

Article L233-8-II of the French Commercial CodeArticle 223-16 of the General Regulations of the AMF (French Financial Markets Authority) PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) March 31, 2025 34,931,012 44,492,548 44,198,744 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. (2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with...

Improved profitability of IRIS Pharma with a net income of 6% of revenues Extended financial visibility to the 2nd quarter of 2026 after the support of the France 2030 plan TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today reports its 2024 full-year results as approved by the Board of Directors at its meeting of March 4, 2025. The audit procedures on the consolidated accounts have been carried out. The certification report has not been issued to date. It will be issued after the completion of the procedures required for the purposes of filing the Universal Registration Document. Selected financial information (as of December 31, 2024/Consolidated financial statements under IFRS) €m 2024 2023 Revenues 4.6 4.6 Cost of goods a...

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) February 28, 2025 34,931,012 44,492,493 44,197,190 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. (2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance ...

TOULOUSE, France & WESTLAKE, Calif.--(BUSINESS WIRE)--ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, announces today that its clinical development in sepsis has been selected as part of the “i-Démo” call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government. After 6 months of examining ABIONYX Pharma's CER-001 Sepsis project, a panel of experts was able to validate and objectify the quality of the project in its scientific, technological and clinical aspects. The CER-001 Sepsis project represents a strategic cornerstone for ABIONYX Pharma, leveraging its unique expertise to use the only recombinant apoA-I protein in the treatment of the most severe inflammation in the human body. The ABIONYX Pharma Sepsis project currently operates on two strategic fronts: An integrated biomedicine approach: AB...

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) December 31, 2024 34,931,012 44,404,824 44,093,499 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. (2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance w...